SCHEMBL16992006

SCHEMBL16992006

COC(=O)c1ccc(CNC(=O)C2CC2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.62
PKM P14618 1/20 0.62
RAB9A P51151 1/20 0.62
ACHE P22303 1/20 0.55
BACE1 P56817 1/20 0.55
ALDH1A1 P00352 5/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
POLB P06746 2/20 0.51
TP53 P04637 2/20 0.50
HSD17B10 Q99714 1/20 0.50
HPGD P15428 4/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
ERCC1 P07992 1/20 0.49
ERCC4 Q92889 1/20 0.49
TSHR P16473 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18310129 0.90 NPC1 (0.62) NPC1PKMRAB9AACHEBACE1
SCHEMBL16991973 0.83 NPC1 (0.55) NPC1PKMRAB9AACHEBACE1
SCHEMBL14782977 0.82 HPGD (0.55) NPC1PKMRAB9AACHEBACE1
SCHEMBL25720038 0.81 MEN1 (0.55) NPC1PKMRAB9AACHEBACE1
SCHEMBL6336112 0.78 ERCC1 (0.69) NPC1PKMRAB9AACHEBACE1
SCHEMBL14782827 0.77 ERCC1 (0.53) NPC1PKMRAB9AALDH1A1SMN1; SMN2
SCHEMBL3264766 0.77 BDKRB1 (0.53) NPC1PKMRAB9AALDH1A1SMN1; SMN2
SCHEMBL4242416 0.77 POLB (0.62) NPC1RAB9AACHEBACE1ALDH1A1
SCHEMBL5503225 0.77 PPARG (0.51) NPC1RAB9AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL24822576 0.76 ALDH1A1 (0.50) ALDH1A1POLBHPGDLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786524-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2023-10-17 US disclosed
US-11786524-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2023-10-17 US disclosed
US-20210275525-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2021-09-09 US disclosed
US-20210275525-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2021-09-09 US disclosed
EP-3811944-A1 PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS Sentinel Oncology Limited (GB) 2021-04-28 EP disclosed
EP-3811944-A1 PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS Sentinel Oncology Limited (GB) 2021-04-28 EP disclosed
US-10973817-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2021-04-13 US disclosed
US-10973817-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2021-04-13 US disclosed
EP-3104860-B1 PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS SENTINEL ONCOLOGY LTD (GB) 2020-12-30 EP disclosed
EP-3104860-B1 PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS SENTINEL ONCOLOGY LTD (GB) 2020-12-30 EP disclosed
CN-110143950-A Medical compounds 西雅图遗传学公司 2019-08-20 CN disclosed
CN-106170288-B Pharmaceutical compounds 西雅图遗传学公司 2019-07-19 CN disclosed
US-20180271860-A1 PHARMACEUTICAL COMPOUNDS CASCADIAN THERAPEUTICS, INC. (US) 2018-09-27 US disclosed
US-10010547-B2 Pharmaceutical compounds CASCADIAN THERAPEUTICS, INC. (US) 2018-07-03 US disclosed
US-10010547-B2 Pharmaceutical compounds CASCADIAN THERAPEUTICS, INC. (US) 2018-07-03 US disclosed
EP-3104860-A1 PHARMACEUTICAL COMPOUNDS Cascadian Therapeutics, Inc. (US) 2016-12-21 EP disclosed
US-20160361310-A1 PHARMACEUTICAL COMPOUNDS SEATTLE GENETICS, INC. 2016-12-15 US disclosed
US-20160361310-A1 PHARMACEUTICAL COMPOUNDS SEATTLE GENETICS, INC. 2016-12-15 US disclosed
CN-106170288-A Pharmaceutical compounds 卡斯卡迪安疗法公司 2016-11-30 CN disclosed
WO-2015120390-A1 PHARMACEUTICAL COMPOUNDS ONCOTHYREON INC. (US) 2015-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010547-B2 Pharmaceutical compounds CHKA, CHKB, TNK2 NPC1 306/4885PKM 397/4885RAB9A 1682/4885
US-20180271860-A1 PHARMACEUTICAL COMPOUNDS CHKA, CHKB, TNK2 NPC1 306/4885PKM 397/4885RAB9A 1682/4885
US-11786524-B2 Pharmaceutical compounds CHKA, CHKB, TNK2 NPC1 306/4885PKM 397/4885RAB9A 1682/4885
US-20160361310-A1 PHARMACEUTICAL COMPOUNDS CHKA, CHKB, TNK2 NPC1 306/4885PKM 397/4885RAB9A 1682/4885
US-20210275525-A1 PHARMACEUTICAL COMPOUNDS CHKA, CHKB, TNK2 NPC1 306/4885PKM 397/4885RAB9A 1682/4885
US-10973817-B2 Pharmaceutical compounds CHKA, CHKB, TNK2 NPC1 306/4885PKM 397/4885RAB9A 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.